Endometrial Cancer
If it’s your first time on this website, please read the disclaimer section.
Oct 12 – Oct 19, 2026
Emerging Therapeutic targets and Early-phase drug Development in Gynecological Malignancies.
ANN ONCOL · Q1 JOURNAL - RANK #4/326TOP-TIER
This review examines emerging molecular targets and early-phase drug development strategies for gynecological malignancies, focusing on overcoming treatment resistance through biomarker-driven therapies. The authors highlight novel agents targeting DNA damage response pathways, such as WEE1 and PKMYT1, alongside specific alterations like TP53 Y220C and the rapid expansion of antibody-drug conjugates. For clinicians, these developments represent a significant shift toward precision oncology, offering potential alternatives to conventional chemotherapy for recurrent or treatment-resistant cancers. While tumor heterogeneity and resistance persist, the integration of these targeted therapies into clinical sequencing protocols is essential for improving patient outcomes in oncology practice.
10.1016/j.annonc.2026.10.101